Dipexium Pharmaceuticals, Inc. on Preliminary List of Additions to Russell Microcap® Index - CBS 3 Springfield - WSHM

Dipexium Pharmaceuticals, Inc. on Preliminary List of Additions to Russell Microcap® Index

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Dipexium Pharmaceuticals, Inc.

NEW YORK, June 23, 2014 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NasdaqCM: DPRX), today announced it was included in the preliminary list of additions to the Russell Microcap® Index according to information posted by Russell Investments on June 13, 2014. The final 2014 reconstitution of the Russell Indexes will take place after the market closes on June 27, 2014 and final membership lists will be posted on June 30, 2014, with trading in the reconstituted indexes commencing that same day.

According to Russell, annual reconstitution of Russell Indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization to create the Russell 3000® Index and Russell Microcap® Index. Inclusion in the Russell Microcap® Index will remain in place for the ensuing 12-month period. The Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.2 trillion in assets currently are benchmarked to Russell Indexes. http://www.russell.com/indexes/americas/indexes/default.page.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NasdaqCM: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate bacterial skin infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). For additional information about the company, please visit www.dipexiumpharmaceuticals.com.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Dipexium Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submission for Locilex®) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Company Contacts:

David P. Luci
President and Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
212-269-2834
davidluci@dipexium.com

or

David Garrett
Vice President, Finance and Corporate Development
Dipexium Pharmaceuticals, Inc.
212-269-2834
davidgarrett@dipexium.com

© 2014 Dipexium Pharmaceuticals, Inc.  All rights reserved.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
WSHM
Powered by WorldNow CNN
All content © 2014, WSHM; Springfield, MA. (A Meredith Corporation Station) and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.